Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
| Market Cap | $521.26M+1.3% |
| Revenue (ttm) | $147.76M+75.1% |
| Net Income | $78.02M+120.8% |
| EPS | $1.20+92.6% |
| Shares Out | 59.50M |
| PE Ratio | 6.84 |
| Forward PE | 9.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,152,866 |
| Open | $8.95 |
| Previous Close | $9.07 |
| Day's Range | $8.70 - $9.17 |
| 52-Week Range | $8.01 - $15.04 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | $24.25(+176.83%) |
| Earnings Date | Mar 8, 2027 |
About ZVRA
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 8, 2027Earnings report
$ZVRA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ZVRA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ZVRA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ZVRA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ZVRA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ZVRA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ZVRA
| VTIVanguard Morningstar Total Stock Market ETF | $15.39M |
| IWMiShares Russell 2000 ETF | $13.85M |
| JSMDJanus Henderson Small/Mid Cap Growth Alpha ETF | $6.97M |
| VXFVanguard Extended Market ETF | $6.93M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $6.89M |
| IBBiShares Biotechnology ETF | $4.10M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ZVRA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Negative EU regulatory opinion on lead drug overshadows analyst optimism; significant setback for European market prospects.
Recent Insider Activity
Insider Score Trend Over Time
-35.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 1.57% |
| FDLS | Inspire Fidelis Multi Factor ETF | 0.97% |
| JSMD | Janus Henderson Small/Mid Cap Growth Alpha ETF | 0.88% |
| JSML | Janus Henderson Small Cap Growth Alpha ETF | 0.81% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.57% |
| BRSV | EA Series Trust - EA Bridgeway Select Small-Cap Value ETF | 0.39% |
| PILL | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | 0.24% |
| BFOR | ALPS ETF Trust - Barron's 400 ETF | 0.23% |
| SFLO | VictoryShares Small Cap Free Cash Flow ETF | 0.23% |
| ROSC | Hartford Multifactor Small Cap ETF | 0.18% |
| IWC | iShares Micro-Cap ETF | 0.17% |
| FSCC | Federated Hermes MDT Small Cap Core ETF | 0.16% |
Weight is the stock’s share of each fund’s holdings.
